AbCellera Biologics Inc. Income Taxes Receivable, Noncurrent
AbCellera Biologics Inc. (ABCL) had Income Taxes Receivable, Noncurrent of $17.40 million as of 2023-06-30, per its 10-Q filed 2023-08-03.
Discontinued › Notes
us-gaap:IncomeTaxesReceivableNoncurrent · last filed 2023-08-03
- 2023-06-30: Income Taxes Receivable, Noncurrent $17.40M.
- 2022-12-31: Income Taxes Receivable, Noncurrent $0.00.
| Period end | Income Taxes Receivable, Noncurrent |
|---|---|
| 2023-06-30 | $17.40M 10-Q · filed 2023-08-03 |
| 2022-12-31 | $0.00 10-Q · filed 2023-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |